Skip to main content

Table 1 Timeline of events

From: Clinical encounter with three cancer patients affected by groundwater contamination at Camp Lejeune: a case series and review of the literature

Time

Patient #1

1985–1992

Lived at Tarawa Terrace

Dec 2020

Diagnosed with acute lymphoblastic leukemia

Started Linker regimen—course 1 (induction)

Achieved complete remission in bone marrow biopsy

Jan–Apr 2021

Linker regimen—courses 2, 3, 4, 5 (consolidation)

May 2021

Allogeneic stem cell transplant

Oct 2021

Last follow-up

Time

Patient #2

1962–1987

Lived at Camp Johnson (formerly called Camp Knox)

Feb 2011

Diagnosed with prostate adenocarcinoma

Apr 2011

Brachytherapy for prostate cancer

Jun 2016

Developed autoimmune hemolytic anemia with a monoclonal B cell lymphocytosis

Treated with steroid and rituximab

Sep 2016

Bone marrow biopsy did not reveal any lymphoproliferative disorder

Oct 2016

Diagnosed with colon adenocarcinoma

Underwent a right hemicolectomy

CT of the chest revealed a 6 mm speculated nodule in the right upper lobe of the lung

Dec 2016–May 2017

Adjuvant chemotherapy (FOLFOX) for colon cancer

Dec 2017

The lung mass increased in size to 1.2 cm in the chest CT

May 2018

The size of the lung mass increased to 1.3 cm with FDG uptake similar to that of the blood pool

May–Jun 2018

Stereotactic body radiation therapy (SBRT) for the lung mass

Sep 2020

Bone marrow biopsy which was performed for persistent thrombocytopenia revealed kappa monotypic B cell lymphocytosis

Sep 2021

Started ibrutinib for CLL

May 2022

Last follow-up

Time

Patient #3

1967–1968

Lived at Hadnot Point and Tarawa Terrace

2002–2020

Recurrent basal cell carcinoma and squamous cell carcinoma in different areas of skin

Dec 2020

Diagnosed with melanoma in the right upper chest

Nov 2020

Wide local excision of skin with no residual disease (melanoma in situ)

Mar 2021

Resection of ethmoid inverted papilloma

Jan 2022

Last follow-up

  1. CLL chronic lymphocytic leukemia, CT computed tomography, FDG, fluorodeoxyglucose